中国血液净化2024,Vol.23Issue(3) :197-199,218.DOI:10.3969/j.issn.1671-4091.2024.03.009

腹膜透析患者包裹性腹膜硬化诊疗进展

Advances in the diagnosis and treatment of encapsulated peritoneal sclerosis in peritoneal dialysis pa-tients

娄芳芳 刘晓怡 谢超 孔耀中
中国血液净化2024,Vol.23Issue(3) :197-199,218.DOI:10.3969/j.issn.1671-4091.2024.03.009

腹膜透析患者包裹性腹膜硬化诊疗进展

Advances in the diagnosis and treatment of encapsulated peritoneal sclerosis in peritoneal dialysis pa-tients

娄芳芳 1刘晓怡 1谢超 1孔耀中1
扫码查看

作者信息

  • 1. 528000 广东,佛山市第一人民医院肾内科
  • 折叠

摘要

腹膜透析(peritoneal dialysis,PD)目前广泛应用于终末期肾病(end stage renal dis-ease,ESRD)患者的长期治疗.包裹性腹膜硬化(encapsulating peritoneal sclerosis,EPS)是长期腹膜透析患者少见的严重并发症,病死率高.EPS的临床症状主要包括不规则、持续或频繁的胃肠道梗阻症状,常伴有剧烈腹痛、恶心和呕吐.影像学多表现为腹膜进行性纤维样增厚、硬化,导致肠包裹,继而出现部分或完全性肠梗阻.本综述旨在从EPS的发病机制及诊疗进展做一介绍.

Abstract

Peritoneal dialysis(PD)is now widely used in the long-term treatment of patients with end stage renal disease(ESRD).Encapsulating peritoneal sclerosis(EPS)is a rare and serious complication of long-term PD patients with a high morbidity and mortality rate.The clinical symptoms of EPS mainly include irregular,persistent or frequent gastrointestinal obstruction symptoms often accompanied by severe abdominal pain,nausea,and vomiting.Imaging mostly shows progressive fibrotic thickening and sclerosis of the perito-neum,leading to intestinal encapsulation and followed by partial or complete intestinal obstruction.The pur-pose of this review is to introduce the pathogenesis of EPS and the progress of its diagnosis and treatment.

关键词

腹膜透析/包裹性腹膜硬化/发病机制/诊断/治疗

Key words

Peritoneal dialysis/Encapsulating peritoneal sclerosis/Pathogenesis/Diagnosis/Treatment

引用本文复制引用

出版年

2024
中国血液净化
中国医院协会

中国血液净化

CSTPCDCSCD
影响因子:1.54
ISSN:1671-4091
参考文献量24
段落导航相关论文